Pooled analysis of bleeding profile, efficacy and safety of oral oestradiol valerate/dienogest in women aged 25 and under

References

• Mansour D. International survey to assess women’s attitudes regarding choice of daily versus nondaily female hormonal contraception. Int J Womens Health. 2014;6:367–375.
   PubMedGoogle Scholar
• Ahrendt HJ, Makalova D, Parke S, et al. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009;80:436–444.
   PubMed Web of Science ®Google Scholar
• Grandi G, Napolitano A, Cagnacci A. Metabolic impact of combined hormonal contraceptives containing estradiol. Expert Opin Drug Metab Toxicol. 2016;12:779–787.
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab. 2013;27:13–24.
   PubMed Web of Science ®Google Scholar
• Wiegratz I, Lee JH, Kutschera E, et al. Effect of four oral contraceptives on hemostatic parameters. Contraception. 2004;70:97–106.
   PubMed Web of Science ®Google Scholar
• Harada T, Taniguchi F. Dienogest: a new therapeutic agent for the treatment of endometriosis. Womens Health (Lond Engl). 2010;6:27–35.
   PubMedGoogle Scholar
• Qlaira (estradiol valerate/dienogest). [cited 2020 Feb 24] Available from: www.medicines.org.uk/emc/product/6536/smpc.
   Google Scholar
• Nelson A, Parke S, Makalova D, et al. Efficacy and bleeding profile of a combined oral contraceptive containing oestradiol valerate/dienogest: a pooled analysis of three studies conducted in North America and Europe. Eur J Contracept Reprod Health Care. 2013;18:264–273.
   PubMed Web of Science ®Google Scholar
• Barnett C, Hagemann C, Dinger J, et al. Fertility and combined oral contraceptives - unintended pregnancies and planned pregnancies following oral contraceptive use – results from the INAS-SCORE study. Eur J Contracept Reprod Health Care. 2017;22:17–23.
   PubMed Web of Science ®Google Scholar
• Briggs P, Serrani M, Vogtlander K, et al. Continuation rates, bleeding profile acceptability, and satisfaction of women using an oral contraceptive pill containing estradiol valerate and dienogest versus a progestogen-only pill after switching from an ethinylestradiol-containing pill in a real-life setting: results of the CONTENT study. IJWH. 2016;8:477–487.
   PubMed Web of Science ®Google Scholar
• Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception. 2016;94:328–339.
   PubMed Web of Science ®Google Scholar
• Borgelt LM, Martell CW. Estradiol valerate/dienogest: a novel combined oral contraceptive. Clin Ther. 2012;34:37–55.
   PubMed Web of Science ®Google Scholar
• Guida M, Bifulco G, Di Spiezio Sardo A, et al. Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill. Int J Womens Health. 2010; Aug 242:279–290.
   PubMedGoogle Scholar
• Junge W, Mellinger U, Parke S, et al. Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin Drug Investig. 2011;31:573–584.
   PubMed Web of Science ®Google Scholar
• Micks E, Jensen JT. Estradiol valerate and dienogest: a novel four-phasic oral contraceptive pill effective for pregnancy prevention and treatment of heavy menstrual bleeding. Womens Health (Lond Engl). 2011;7:513–524.
   PubMedGoogle Scholar
• Merki-Feld GS, Caetano C, Porz TC, et al. Are there unmet needs in contraceptive counselling and choice? Findings of the European TANCO Study. Eur J Contracept Reprod Health Care. 2018;23:183–193.
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Guillebaud J. The 7-day contraceptive hormone-free interval should be consigned to history. BMJ Sex Reprod Health. 2018;44:214–220.
   PubMed Web of Science ®Google Scholar
• WHO. Adolescent health and development 2018 [cited 2018 July]. Available from: http://www.searo.who.int/entity/child_adolescent/topics/adolescent_health/en/
   Google Scholar
• Mishell DR, Jr., Guillebaud J, Westhoff C, et al. Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials. Contraception. 2007;75:11–15.
   PubMed Web of Science ®Google Scholar
• Macias G, Merki-Feld GS, Parke S, et al. Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: results from the multicentre, randomised, double-blind, active-controlled HARMONY II study. J Obstet Gynaecol. 2013;33:591–596.
   PubMedGoogle Scholar
• Zeun S, Lu M, Uddin A, et al. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care. 2009;14:221–232.
   PubMed Web of Science ®Google Scholar
• Fruzzetti F, Tremollieres F, Bitzer J. An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest. Gynecol Endocrinol. 2012;28:400–408.
   PubMed Web of Science ®Google Scholar
• Jensen JT, Parke S, Mellinger U, et al. Hormone withdrawal-associated symptoms: comparison of oestradiol valerate/dienogest versus ethinylestradiol/norgestimate. Eur J Contracept Reprod Health Care. 2013;18:274–283.
   PubMed Web of Science ®Google Scholar
• Klipping C, Duijkers I, Parke S, et al. Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Drugs R D. 2011;11:159–170.
   PubMedGoogle Scholar
• ESHRE Capri Workshop Group. Noncontraceptive health benefits of combined oral contraception. Hum Reprod Update. 2005;11:513–525.
   PubMed Web of Science ®Google Scholar